Oragenics Inc(OGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:34 AM ET (Korea 9/30 20:34)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.58 | Insider Own | 0.17% | Shs Outstand | 4.5M | Perf Week | -7.69% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.5M | Perf Month | -8.43% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 1.5% | Short Float | 17.92% | Perf Quarter | -17.33% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -2.81% | Short Ratio | 26.07 | Perf Half Y | -4.72% |
| Sales | 0.00B | P/B | 0.59 | EPS next 5Y | - | ROA | -264.23% | Short Interest | 0.81M | Perf YTD | -38.71% |
| Book/sh | 0.81 | P/C | 0.56 | EPS past 3/5Y | 72.24% 64.78% | ROE | -1307.06% | 52W High | -66.9% ($1.45) | Perf Year | -64.18% |
| Cash/sh | 0.85 | P/FCF | - | Sales past 3/5Y | - | ROIC | -274.7% | 52W Low | 4.23% ($0.46) | Perf 3Y | -99.46% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 86.26% | Gross Margin | - | Volatility(W/M) | 7.32% 5.94% | Perf 5Y | -99.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.03 | Perf 10Y | -99.99% |
| Dividend Ex-Date | - | Quick Ratio | 3.01 | EPS Q/Q | 81.61% | Profit Margin | - | RSI (14) | 43.92 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.01 | Sales Q/Q | - | SMA20 | -3.83% ($0.5) | Beta | 1.27 | Target Price | $2 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -6.88% ($0.52) | Rel Volume | 1.38 | Prev Close | $0.47 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -26.65% ($0.65) | Avg Volume(3M) | 0.03M | Price | $0.48 |
| IPO | 2003/10/21 | Option/Short | No/Yes | Trades | 127 | Volume | 42,637 | Change | 1.78% |
🧠 A clinical-stage biotech developing therapies for neurological and central nervous system disorders. The company possesses an innovative intranasal delivery technology that administers drugs directly to the brain.
Over the past 1 year, on the lower side
67% below its 1-year high.
Traded more than usual That is 138% of its average volume.
OGEN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +76% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
HYDR Global X Hydrogen ETF 94M 
FRNW Fidelity Clean Energy ETF 90M 
IBAT iShares Energy Storage & Materials ETF 62M 
CTEX ProShares S&P Kensho Cleantech ETF 5M It ranks #586 of 592 in the industry
Based on market cap of $2M.
FAQ
What kind of company is OGEN?
OGEN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OGEN?
The market cap of OGEN is approximately $2M, ranking 5,841 within its sector.
What is the 52-week high and low for OGEN?
OGEN has recorded a 52-week high of $1.45 and a low of $0.46.
